Your shopping cart is currently empty

p-Cresyl Sulfate is the major uremic toxin present in the blood of patients with chronic kidney disease and is derived from the metabolites of tyrosine and phenylalanine in the liver.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $51 | In Stock | In Stock | |
| 5 mg | $122 | In Stock | In Stock | |
| 10 mg | $197 | In Stock | In Stock | |
| 25 mg | $347 | In Stock | In Stock | |
| 50 mg | $516 | In Stock | In Stock | |
| 100 mg | $736 | - | In Stock | |
| 500 mg | $1,480 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $117 | In Stock | In Stock |
| Description | p-Cresyl Sulfate is the major uremic toxin present in the blood of patients with chronic kidney disease and is derived from the metabolites of tyrosine and phenylalanine in the liver. |
| In vitro | METHODS: H9C2 cardiomyocytes were treated with p-Cresyl Sulfate (3.125, 6.25, 12.5, 25.0 μg/mL) to study the changes in cell proliferation, cell size and mitochondrial parameters, including morphology, respiration, biogenesis and membrane potential. RESULTS The lowest effective dose of p-Cresyl Sulfate (6.25 μg/mL) induced mitochondrial hypertransfusion, enhanced mitochondrial connectivity, increased mitochondrial oxygen consumption rate, mitochondrial mass, mitochondrial DNA copy number and cardiomyocyte volume; at the same time, p-Cresyl Sulfate increased the phosphorylation of energy-sensing adenosine monophosphate-activated protein kinase (AMPK), but did not induce cell apoptosis. [2] |
| In vivo | METHODS: Mice with AKI induced by ischemia and reperfusion (IR) injury were treated with p-Cresyl Sulfate (20, 40, or 60 mg/L/day for 15 days) to evaluate the effects of p-Cresyl Sulfate administration on renal and cardiac function. RESULTS p-Cresyl Sulfate at a dose of 20 mg/L resulted in decreased renal mass, increased cystatin C and kidney injury molecule 1 (KIM-1) gene expression, and decreased α-actin in the heart. [3] |
| Molecular Weight | 188.20 |
| Formula | C7H8O4S |
| Cas No. | 3233-58-7 |
| Smiles | O(S(=O)(=O)O)C1=CC=C(C)C=C1 |
| Relative Density. | 1.428 g/cm3 (Predicted) |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 250.00 mg/mL (1328.37 mM), Sonication is recommended. H2O: 100.00 mg/mL (531.35 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5.00 mg/mL (26.57 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
H2O/DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.